
A recent study delves into the intricate relationship between anti-CD20 monoclonal antibodies, immunoglobulin G (IgG) levels, and infection risks in multiple sclerosis (MS) treatment. Through a comprehensive review of 39 studies encompassing 20,501 MS patients, findings revealed an 11% prevalence of hypogammaglobulinemia, with rituximab showing the highest occurrence at 18%. Subgroup analyses highlighted varying prevalence rates based on drug type and treatment duration. Pulmonary infections emerged as the most prevalent, urging clinicians to weigh risks when considering anti-CD20 therapies for MS management.
Like
Save
Share